Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 5/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405013 | 0.91 | CHRNA7 (0.63) | MAPK14CHRNA7MMP13MMP2CYP3A4 | |
| SCHEMBL3402537 | 0.90 | MAPK14 (0.61) | MAPK14MMP13CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3404728 | 0.88 | CHRNA7 (0.48) | MAPK14CHRNA7MMP13MMP2CYP3A4 | |
| SCHEMBL3430068 | 0.87 | KMT2A (0.56) | MMP13HTTSMN1; SMN2 | |
| SCHEMBL3425212 | 0.86 | METTL3 (0.48) | MAPK14CHRNA7MMP13MMP2CYP3A4 | |
| SCHEMBL3400492 | 0.85 | EPHX2 (0.58) | CYP3A4HTTSMN1; SMN2HPGDLMNA | |
| SCHEMBL3401577 | 0.84 | NR1H4 (0.59) | SMN1; SMN2HPGDNLRP3MAPT | |
| SCHEMBL3427835 | 0.82 | EPHX2 (0.59) | MAPK14CHRNA7NLRP3 | |
| SCHEMBL3428967 | 0.81 | HPGD (0.60) | MAPK14CHRNA7MMP13CYP3A4HTT | |
| SCHEMBL4300349 | 0.80 | CHRNA7 (0.51) | MAPK14CHRNA7SMN1; SMN2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | claimed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | claimed |
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | disclosed |
| EP-2250162-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009100294-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA2, CHRNA4, CHRNA5 | MAPK14 2264/4885CHRNA7 8/4885MMP13 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.